Literature DB >> 34303561

Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2?

Felipe Inserra1, Carlos Tajer2, Laura Antonietti2, Javier Mariani2, León Ferder1, Walter Manucha3.   

Abstract

Entities:  

Keywords:  SARS-CoV-2 vaccines; immune response; vitamin D

Year:  2021        PMID: 34303561      PMCID: PMC8282476          DOI: 10.1016/j.vaccine.2021.07.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


× No keyword cloud information.
Letter to editor The unprecedented worldwide dissemination of SARS-CoV-2 infection, has challenged scientists, governments and pharmaceutical industry in halting this pandemic in a context of profound uncertainty. Multiple prophylactic and therapeutic strategies have been evaluated in a short time, driven by the urgent need of preventing COVID-19 spread and worldwide mortality. Fortunately, the impressive and massive international effort of scientists, organizations, governments and pharmaceutical industry concluded in the development of several effective vaccines, with unprecedented speed and scale, which undoubtedly are an invaluable tool for preventing COVID-19, although duration of vaccine protections is not yet clearly defined. COVID-19 vaccines can elicit not only neutralizing antibodies (with detectable antibodies ranges from 50 to 94%), but also SARS-CoV-2-specific CD4+ and CD8+ T-cell responses. Nevertheless, the relevant measures of vaccine performance are vaccine efficacy (reduced risk of infection or disease among vaccinated individuals under controlled circumstances estimated from clinical trials), vaccine effectiveness (reduced risk of infection, symptomatic and severe disease among vaccinated individuals in real-world conditions estimated from observational studies) and vaccine impact (reduction in incidence of infection or disease in a population where some members are vaccinated) [1]. The latter depends on vaccine coverage and results from direct effects of vaccination, as well as herd protection. In a complex landscape of COVID-19 vaccine access inequities, some low-income countries are deferring second doses, delaying the achievement of vaccine impact. In this context, optimizing vaccines effectiveness (performance in real world) is of paramount importance. The use of adjuvant strategies to improve responses to viral vaccines seems a helpful approach, particularly in immunosuppressed and immunosenescent persons [2]. Of interest, nutritional interventions are one of the possible approaches to improve vaccination response [3]. Multiple previous studies conclude that the supplementation of micronutrients such as vitamin D has a protective effect against some viral infections such as the common cold, influenza and dengue [4]. The approach of optimizing COVID-19 vaccines efficacy through vitamin D supplementation is currently being evaluated in numerous clinical trials [5]. In the meanwhile, due to its excellent toxic-therapeutic margin, the critical epidemiological situation, and the biological plausibility of its positive effect, especially in a context in which restrictive measures may have negatively impacted its serum levels, it seems appropriate to consider vitamin D supplementation to prevent and/or attenuate COVID-19 [6]. It has been observed an inverse correlation between vitamin D serum levels and the risk of SARS-CoV-2 infection and disease severity [7], [8]. Insufficient vitamin D status, as defined by a low circulating level of 25-OH-D is associated with a reduced immune response to influenza vaccination, and to highlight, Ming-Dar et al. observed lower seroprotection rates of influenza A virus subtype H3N2 (A/H3N2) and B strain in vitamin D deficiency patients than patients with normal vitamin D levels [9]. The effect of vitamin D on immune system has been recognized [10], [11], [12]. Specifically, at a cellular and molecular level, vitamin D preferentially targets helper T cell activity (Th1) by inhibiting the secretion of both IL-2 and IFN-gamma by Th1 and by suppressing the secretion pro-Th1 cytokine IL-12 by antigen- presenting cells [13]. COVID-19 patients with low serum vitamin D levels have a reduction in CD8+ T lymphocytes with a low CD4 / CD8 ratio [14]. Furthermore, it has long been recognized that a large percentage of the worldwide population has low levels of vitamin D [15], [16], [17], which could currently be exacerbated by restrictive measures and their impact on sun exposure. Vitamin D supplementation could optimize the ability of the immune system to respond appropriately to COVID-19 vaccination. Routine dosing of vitamin D serum levels is neither usual nor inexpensive practice, and in knowledge of the significant percentage of the population that has shown to present vitamin D deficiency. Thus, awaiting the results of ongoing prospective studies, we encourage the scientific community considering vitamin D supplementation as a cost-effective, risk-free and inexpensive strategy that could have a great impact on optimizing the immune response to COVID-19 vaccines.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  7 in total

Review 1.  A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency.

Authors:  Gerry K Schwalfenberg
Journal:  Mol Nutr Food Res       Date:  2010-09-07       Impact factor: 5.914

Review 2.  The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system.

Authors:  Marcelo Ferder; Felipe Inserra; Walter Manucha; León Ferder
Journal:  Am J Physiol Cell Physiol       Date:  2013-01-30       Impact factor: 4.249

Review 3.  Immunosenescence: Influenza vaccination and the elderly.

Authors:  Kamran Haq; Janet E McElhaney
Journal:  Curr Opin Immunol       Date:  2014-04-25       Impact factor: 7.486

4.  Vitamin D3 metabolite calcidiol primes human dendritic cells to promote the development of immunomodulatory IL-10-producing T cells.

Authors:  Ghaith Bakdash; Toni M M van Capel; Lauren M K Mason; Martien L Kapsenberg; Esther C de Jong
Journal:  Vaccine       Date:  2014-09-16       Impact factor: 3.641

5.  Is sunlight enough for sufficient vitamin D status in children and adolescents? A survey in a sunny region of southern Italy.

Authors:  Irene Rutigliano; Gianpaolo De Filippo; Donatella De Giovanni; Angelo Campanozzi
Journal:  Nutrition       Date:  2020-12-05       Impact factor: 4.008

6.  High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).

Authors:  Javier Mariani; Carlos Tajer; Laura Antonietti; Felipe Inserra; León Ferder; Walter Manucha
Journal:  Trials       Date:  2021-02-01       Impact factor: 2.279

7.  Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies.

Authors:  Fausto Petrelli; Andrea Luciani; Gianluca Perego; Giuseppina Dognini; Paolo Luigi Colombelli; Antonio Ghidini
Journal:  J Steroid Biochem Mol Biol       Date:  2021-03-26       Impact factor: 4.292

  7 in total
  2 in total

1.  Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2.

Authors:  Paola Zelini; Piera d'Angelo; Emanuele Cereda; Catherine Klersy; Peressini Sabrina; Riccardo Albertini; Giuseppina Grugnetti; Anna Maria Grugnetti; Carlo Marena; Sara Cutti; Daniele Lilleri; Irene Cassaniti; Baldanti Fausto; Riccardo Caccialanza
Journal:  Biomedicines       Date:  2022-08-17

2.  Adipokines, and not vitamin D, associate with antibody immune responses following dual BNT162b2 vaccination within individuals younger than 60 years.

Authors:  Mariana Pavel-Tanasa; Daniela Constantinescu; Corina Maria Cianga; Ecaterina Anisie; Ana Irina Mereuta; Cristina Gabriela Tuchilus; Petru Cianga
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.